Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial
Journal of Human Immunity · 07.09.2026 · 2 (5)
DOI: 10.70962/jhi.20250256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 23.06.2026. Verfasst von Toshinao Kawai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, National Center for Child Health and Development, Tokyo, Japan. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, National Center for Child Health and Development.
Abstract (Originalsprache)
Chronic granulomatous disease–related inflammatory bowel disease (CGD-IBD) requires effective and safe therapies, as conventional immunosuppressants increase infection risk. Thalidomide, with anti-inflammatory and immunomodulatory effects, may represent a therapeutic option. This study was conducted to explore the preliminary efficacy and safety of thalidomide for CGD-IBD in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II trial. Patients were randomized to thalidomide or placebo for a 12-wk blinded phase, followed by a 12-wk extension thalidomide phase. The primary endpoint was achievement of remission or a ≥20-point reduction in the Pediatric Ulcerative Colitis Activity Index. Eight male patients were randomized and analyzed. The primary endpoint was achieved by 1/3 of thalidomide patients versus 0/5 in the placebo group during the blinded phase, and by 5/8 in the extension phase. Secondary endpoints and exploratory endoscopy showed improvements. CGD-related infection rates were comparable before and after treatment. Thalidomide met the prespecified efficacy criterion with an acceptable safety profile in CGD-IBD, suggesting a promising therapeutic option that warrants further clinical studies.
Autor:innen und Institutionen
- Division of Immunology, National Center for Child Health and Development, Tokyo, Japan.
- Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
- Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
- Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
- Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
ORCID-Profile: Toshinao Kawai, Mayumi Sako, Katsuhiro Arai, Takashi Ishikawa, Tomoko Toma, Taizo Wada, Yutaro Yada, Masataka Ishimura, Takehiko Doi, Satoshi Okada, Hiroshi Moritake, Kazushi Izawa, Masahiro Ueki, Eisuke Inoue, Hidefumi Nakamura, Masafumi Onodera
Förderung
- Japan Agency for Medical Research and Development
- National Center for Child Health and Development
Zitieren
APA
Kawai, T., Sako, M., Arai, K., Ishikawa, T., Toma, T., Wada, T., Yada, Y., Ishimura, M., Doi, T., Okada, S., Moritake, H., Izawa, K., Ueki, M., Inoue, E., Nakamura, H., & Onodera, M. (2026). Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial. Journal of Human Immunity, 2(5). https://doi.org/10.70962/jhi.20250256
Vancouver
Kawai T, Sako M, Arai K, Ishikawa T, Toma T, Wada T, et al. Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial. Journal of Human Immunity. 2026;2(5). doi:10.70962/jhi.20250256
BibTeX
@article{Kawai2026,
author = {Kawai, Toshinao and Sako, Mayumi and Arai, Katsuhiro and Ishikawa, Takashi and Toma, Tomoko and Wada, Taizo and Yada, Yutaro and Ishimura, Masataka and Doi, Takehiko and Okada, Satoshi and Moritake, Hiroshi and Izawa, Kazushi and Ueki, Masahiro and Inoue, Eisuke and Nakamura, Hidefumi and Onodera, Masafumi},
title = {Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial},
journal = {Journal of Human Immunity},
year = {2026},
volume = {2},
number = {5},
doi = {10.70962/jhi.20250256}
}
EUVIMED